GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » EBIT

Provention Bio (Provention Bio) EBIT : $-126.12 Mil (TTM As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Provention Bio EBIT?

Provention Bio's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2022 was $-38.83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was $-126.12 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Provention Bio's annualized ROC % for the quarter that ended in Dec. 2022 was -260.22%. Provention Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -6,368.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Provention Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -5.66%.


Provention Bio EBIT Historical Data

The historical data trend for Provention Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio EBIT Chart

Provention Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial -26.81 -44.37 -99.10 -115.43 -125.92

Provention Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.83 -29.08 -29.83 -28.38 -38.83

Competitive Comparison of Provention Bio's EBIT

For the Biotechnology subindustry, Provention Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provention Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provention Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Provention Bio's EV-to-EBIT falls into.



Provention Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provention Bio  (NAS:PRVB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Provention Bio's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

ROC % (Q: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2022 ) + Invested Capital (Q: Dec. 2022 ))/ count )
=-160.676 * ( 1 - 15.99% )/( (16.557 + 87.187)/ 2 )
=-134.9839076/51.872
=-260.22 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Provention Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2022  Q: Dec. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-155.324/( ( (2.352 + max(-20.205, 0)) + (2.526 + max(-80.744, 0)) )/ 2 )
=-155.324/( ( 2.352 + 2.526 )/ 2 )
=-155.324/2.439
=-6,368.35 %

where Working Capital is:

Working Capital(Q: Sep. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.913) - (12.04 + 7.775 + 5.303)
=-20.205

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.359 + 1.231 + 7.056) - (65.41 + 17.686 + 7.294)
=-80.744

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Provention Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2022 )
=-126.123/2226.533
=-5.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provention Bio EBIT Related Terms

Thank you for viewing the detailed overview of Provention Bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Provention Bio (Provention Bio) Business Description

Traded in Other Exchanges
N/A
Address
55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.
Executives
Sessa Capital (master), L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer director, 10 percent owner, officer: President and CEO PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon director, 10 percent owner, officer: Chief Scientific Officer C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel officer: Chief Accounting Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien officer: Chief People Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi officer: Chief Operations Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio officer: Chief Quality Officer ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos officer: Chief Medical Officer & COO ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche officer: Chief Financial Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701